FDA Classifies Wound Bacteria Detector to Speed Up Patient Care
Published Date: 6/2/2025
Rule
Summary
The FDA is officially classifying devices that detect bacterial activity in chronic wound fluid as Class II, meaning they’ll follow special safety rules. This change helps make sure these devices are safe and work well, while also making it easier for patients to get new, helpful technology. Device makers should get ready for these new rules, which aim to speed up innovation without extra costs.
Analyzed Economic Effects
2 provisions identified: 2 benefits, 0 costs, 0 mixed.
Device Now Classified as Class II
The FDA is officially classifying devices that detect bacterial protease activity in chronic wound fluid as Class II (special controls). The rule says these special controls will be codified and that this classification provides a reasonable assurance of the device's safety and effectiveness and will help enhance patients' access to innovative devices by reducing regulatory burdens.
Special Controls Affect Device Makers
Manufacturers of devices that detect bacterial protease activity in chronic wound fluid will be subject to Class II special controls that the FDA will codify. The agency says this classification reduces regulatory burdens and is intended to speed innovation.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-16959, Frequently Asked Questions-Developing Potential Cellular and Gene Therapy Products; Final Guidance for Industry; Availability
The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance titled "Frequently asked Questions--Developing Potential Cellular and Gene Therapy Products." The guidance document provides industry with answers to frequently asked questions (FAQs) and commonly faced issues that arise during the development of cellular and gene therapy (CGT) products. The FAQs represent common questions directed to the Agency and span multiple disciplines, including regulatory review; chemistry, manufacturing, and controls (CMC); pharmacology/toxicology; clinical; and clinical pharmacology. This guidance announced in this notice finalizes the draft guidance of the same title issued on November 19, 2024.
2026-16939, GNT USA, LLC.; Filing of Color Additive Petition
The Food and Drug Administration (FDA or we) is announcing that we have filed a petition, submitted by GNT USA, LLC., c/o Exponent, Inc., proposing that we amend our color additive regulations to provide for the safe use of safflower (Carthamus tinctorius L.) extract as a color additive in various foods at levels consistent with good manufacturing practices.
2026-16942, Food Additives Permitted in Feed and Drinking Water of Animals; Chromium DL-methionine Chelate
The Food and Drug Administration (FDA, we, or the Agency) is amending the regulations for food additives permitted in feed and drinking water of animals to provide for the safe use of chromium DL- methionine chelate as a nutritional source of chromium in cattle feed. This action is in response to a food additive petition filed by Zinpro Corp.
Previous / Next Documents
Previous: 2025-09878, Safety Zone; City of Duluth Fourth Fest, Duluth, MN
On July 4, 2025, from 9:30 p.m. to 11 p.m., the Coast Guard will set up a safety zone near Bayfront Park in Duluth for the Fourth Fest fireworks. Boats can’t enter, pass through, or anchor in this area unless they get special permission. This keeps everyone safe on the water during the big celebration without any extra costs for the public.
Next: 2025-09885, Airworthiness Directives; Pilatus Aircraft Ltd. Airplanes
If you own a Pilatus PC-24 airplane, listen up! The FAA is updating rules to replace certain titanium bolts with stronger steel ones in the rudder trim system to keep your plane safe. You’ll need to swap out these parts soon and stop using the old bolts to avoid any safety risks.